Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

374.50DKK
28 Apr 2017
Change (% chg)

kr.6.50 (+1.77%)
Prev Close
kr.368.00
Open
kr.368.00
Day's High
kr.376.00
Day's Low
kr.366.50
Volume
199,882
Avg. Vol
206,819
52-wk High
kr.376.00
52-wk Low
kr.197.00

BAVA.CO

Chart for BAVA.CO

About

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate... (more)

Overall

Beta: 1.20
Market Cap(Mil.): kr.11,768.12
Shares Outstanding(Mil.): 31.42
Dividend: --
Yield (%): --

Financials

  BAVA.CO Industry Sector
P/E (TTM): 835.96 29.08 30.08
EPS (TTM): 0.45 -- --
ROI: 1.76 13.73 13.25
ROE: 1.82 14.68 14.41

BRIEF-Valneva signs new EB66 commercial license with Bavarian Nordic

* Announces signing of a new EB66 commercial license with Bavarian Nordic

Apr 18 2017

BRIEF-Bavarian Nordic FY EBIT rises to DKK 33.0 million

* FY revenue 1.01 billion Danish crowns ($145 million) versus 1.02 billion crowns year ago

Mar 15 2017

BRIEF-Bavarian Nordic: collaboration to evaluate CV301 and Tecentriq in bladder cancer

* Announces collaboration to evaluate CV301 and tecentriq in bladder cancer

Mar 10 2017

BRIEF-Bavarian Nordic announces 6-mth follow-up data from phase 1 trial of MVA-BN RSV

* Updated Phase 1 Data Show Bavarian Nordic's Vaccine Candidate Induces a Broad and Durable Immune Response against RSV

Feb 23 2017

BRIEF-Bavarian Nordic Q3 EBIT swings to profit of DKK 124.8 million

* Q3 revenue 452.3 million Danish crowns ($68.1 million) versus 79.1 million crowns year ago

Nov 09 2016

More From Around the Web

Earnings vs. Estimates